Can you believe this? Ticagrelor approved for Primary Prevention of STEMI

It’s all happening. FDA approves Ticagrelor for high-risk cad primary prevention and stroke. I am sure, even Astra Zenica wouldn’t have expected this. At best, the evidence from THEMIS for this Indication, can be called as a statistical extrapolation of comical proportion.  Meanwhile, Ticagrelor thanks Aspirin for its extreme kindness for agreeing to co-live with it.   The twitter reacts. This one is fromDr. Davide Capodanno , current Editor In chief , of  EuroIntervention, the journal with one of the top Impact factor with a huge following. New FDA label for ticagrelor in "high-risk CAD patients", following THEMIS. But: 1) THEMIS was in CAD and DM: what does "high risk" mean? And where is DM?2) NNT and NNH in THEMIS were 125 and 83, with more ICH.A bit surprised by the broad indication.https://t.co/6JyyWpbu6Y— Davide Capodanno (@DFCapodanno) June 1, 2020
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: Uncategorized fda approves ticagrelor THEMIS TRIAL ticagrelor for primary prevetnion Source Type: blogs